• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Medical

Phase 2a study of Pieris and AstraZeneca’s elarekibep DPI discontinued

According to Pieris Pharmaceuticals, AstraZeneca has stopped a Phase 2a trial of elarekibep (PRS-060/AZD1402), an inhaled IL-4 receptor alpha inhibitor that the companies were developing for the treatment of asthma. In the announcement, Pieris said that it has been informed by AstraZeneca that pathology results from a 13-week toxicology study of inhaled dry powder … [Read more...] about Phase 2a study of Pieris and AstraZeneca’s elarekibep DPI discontinued

Vistagen reports results of Phase 1 study of itruvone (PH10) nasal spray

Vistagen said that a Phase 1 study of itruvone (PH10) nasal spray, which the company is developing for the treatment of major depressive disorder, found that itruvone was well tolerated with no serious adverse events. The company had announced the initiation of the study to evaluate a new formulation of PH10 in January 2023. PH10 for the treatment of major … [Read more...] about Vistagen reports results of Phase 1 study of itruvone (PH10) nasal spray

Acadia Pharmaceuticals to develop intranasal carbetocin for the treatment of hyperphagia in PWS

Acadia Pharmaceuticals announced that it will develop ACP-101 (formerly LV-101) intranasal carbetocin for the treatment of excessive hunger in Prader-Willi syndrome (PWS). Acadia acquired the rights to the nasal spray when it acquired Levo Therapeutics in June 2022. Levo had licensed the intranasal carbetocin from Ferring Pharmaceuticals in 2017 and initiated Phase 3 … [Read more...] about Acadia Pharmaceuticals to develop intranasal carbetocin for the treatment of hyperphagia in PWS

Vistagen announces results from Phase 2a trial of PH80 epoxyestrenolone nasal spray for the treatment of hot flashes

Vistagen announced that a Phase 2a trial of the company's PH80 intranasal epoxyestrenolone in menopausal women experiencing hot flashes demonstrated statistically significant reduction in the frequency and severity of the hot flashes. The company acquired PH80 when it acquired Pherin Pharmaceuticals earlier this year and the Phase 2a trial was conducted by Pherin at … [Read more...] about Vistagen announces results from Phase 2a trial of PH80 epoxyestrenolone nasal spray for the treatment of hot flashes

InhaleRx initiates Phase 1 trial of IRX211 dronabinol MDI

Australian inhaled cannabis developer InhaleRx (formerly Lifespot Health) announced the initiation of a Phase 1 SAD study of the company's IRX211 inhaled dronabinol, a synthetic THC. According to the company, IRX211 was formulated by "a specialized inhalation expert group based in the UK," and the clinical trial batch was manufactured by Ab Initio Pharma. InhaleRx is … [Read more...] about InhaleRx initiates Phase 1 trial of IRX211 dronabinol MDI

Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury

Alpha Cognition announced that the Army Medical Research and Material Command has awarded the company a $750,000 grant to support a pre-clinical study of the possible use of ALPHA-1062 Intranasal galantamine for the treatment of blast-induced mild traumatic brain injury (mTBI). According to Alpha Cognition, the study will be conducted in partnership with the Seattle … [Read more...] about Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury

Altamira says trial of Bentrio bentonite-based nasal spray for SAR met its primary endpoint

Altamira Therapeutics announced that the NASAR trial comparing its Bentrio bentonite-based gel nasal spray to saline nasal spray in patients with seasonal allergic rhinitis met its primary endpoint, demonstrating a statistically significant reduction in nasal allergy symptoms. The OTC nasal spray is currently available in Germany and has received 510(k) clearance in … [Read more...] about Altamira says trial of Bentrio bentonite-based nasal spray for SAR met its primary endpoint

Aerami says it will advance AER-901 inhaled imatinib into a Phase 2 trial for PAH and PH-ILD

Aerami Therapeutics said that pre-clinical and Phase 1 data presented recently at ATS support advancing the company's AER-901 nebulized imatinib into a Phase 2 trial that will include both patients with pulmonary arterial hypertension (PAH) and patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company said that it expects to … [Read more...] about Aerami says it will advance AER-901 inhaled imatinib into a Phase 2 trial for PAH and PH-ILD

Ceapro presents pre-clinical data from study of inhalable yeast beta glucan

Ceapro has presented results from a pre-clinical study of inhalable yeast beta glucans processed with the company's pressurized gas expanded (PGX) technology at ATS, the company said. The study, which was conducted in collaboration with McMaster University, evaluated the aerosolization characteristics of inhaled PGX-processed yeast beta glucans (PGX-YBG) and the … [Read more...] about Ceapro presents pre-clinical data from study of inhalable yeast beta glucan

Lumen Bioscience to develop antiviral intranasal powder for US Department of Defense

Lumen Bioscience said that it has received a contract worth $8.8 million from the Defense Innovation Unit (DIU) of the US Department of Defense for development of "a prototype broad-spectrum, fast-acting intranasal powder for treatment and prevention of known and emerging viral respiratory infections." The funding is part of "Project Panacea," run by DIU and the Joint … [Read more...] about Lumen Bioscience to develop antiviral intranasal powder for US Department of Defense

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Interim pages omitted …
  • Page 119
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews